- NewsCategory：
- All Company news Industry news
common105One result
-
0919
IBio’s Collaboration♣ with South Africa’s AzarGen Biotechn→ <ologies Advances to Next &↕Stage
iBio, Inc. today announced that it has en γ<tered into the initial Stateme∞±✔≥nt of Work (“SOW1”) under i★'ts Memorandum of Understanding (“MOU”) with AzarG↑₩εen Biotechnologies (Pty.) Ltd. (“AzarGen”).Follλ≈owing iBio’s successful use of its ♠φ ≠technologies and manufacturing capabilities to a↕÷>dvance the developme←λε©nt of AzarGen’s surfactant protein therap€"∑eutic through an initial assessmen♠t of production feasibility, in May 2017,→★± the two companies expanded their colγ laboration by initiating the de¥♣velopment of a plant-made rituximab for the Sou∑↓th African market under the MOU.Pursuant to t™✔he SOW1, iBio will manufacture research quant↕ ∑ities of a plant-made rituximab f♣$↓or AzarGen using iBio’s proprietary FastPharmiδ≤σεng™ System. Following₹™₹ batch production, the drug product &£∏candidate will undergo testing v&σ±✘ia iBio CDMO’s bioanalyti∏♦ cal services.“After demonstrating the success of our platform throu ± ₽gh our opening project with →₽↕&AzarGen, we are now advancing to t ↔he next stage of the two companies’ collabora"≠♠≠tion,” commented Robert B.β☆ Kay, iBio’s Chairman and CEO. “We look forward∞σ± to helping AzarGen develop a plant-based, b↓↑io-similar rituximab product for the South A₹♦↔ frican market.”“The early •success in combining iBio’s anδ∞d AzarGen's advanced genetic e™σngineering and synthetic biol≥•βogy techniques in plants rea÷ πlly empowered us to evolve our business plans and•₹↑ product priorities to initiate devel♠←'σopment of a biosimilar version of rituxim πab,” said Dr. Mauritz Venter, CEO of↑"♦ AzarGen. “As we continue to move "&λtoward the initiation of ad↑ vanced pre-clinical act ♥₽ivities, we are conf♦♣↔¶ident that iBio CDMO is ideally suited t₽"♦o provide us with the requisite long-t¥₹erm process development aΩ₩ €nd cGMP manufacturing support. We are•←₹ excited to take this important stγ≈ep forward in advancing this programδ✔•. Focusing on accessib←♣✘ility and affordability of bi♦&ological medicine fo™εr the African continent, we₽↓ look forward to initiating additional proje©±σcts with iBio as we progress.”↔÷Rituximab was first approved by the U.S≠₹Ω . Food and Drug Administr↑©ation in 1997 for treatment of certain B cell ♣ →non-Hodgkin lymphomas. Since tha±t time, its clinical uses have expanded tα©☆πo encompass treatmenγλβ t of chronic lymphocytic leukemia, as weφ₽ll as a range of auto→$✔immune diseases, including certain ty₩$δpes of rheumatoid arthritis. Rituximab hasσ✘↓☆ been placed on the ≈♣φ∑World Health Organization’s List of E÷±≤★ssential Medicines and it was ranked as one o®f the world’s top-10 selling pharmaceuticals ✔∞®in 2018.2019 Asia-pacific pharma<$ IP Leader Summit: http://en.zenseegroup.co≤m/p/404716/ will be held in Beijing&nb✘'$↔sp; on November 1× ♣4-15, and will attrac₩•₽t more than 500 industry experts fr≥&↓om domestic and foreign pharmaceutical companies,&® biotechnology companies, governments, assocσ÷↓iations, law firms, i>∑≤ntellectual property agents and othσ≥∞er companies to atte₹€★≠nd.Official registration and consultati♣←on channels:Contact：AnnPhone: 021-65650305Em↑≤ail：Marketing@zenseegroup.comhttp://ww↓✔♥≈w.zenseegroup.com/for✔π¶ms/view/22113/ -
0918
Hansoh Pharma and Atomwise start strategic colλ↕♠♥laboration on AI drug discovery for multiple ther←♠©→apeutic areas
Major Chinese biopharmaceutical companΩφδδy Hansoh Pharmaceutical Group Compa∞φδφny Limited (Hanmori ∏★∑Pharmaceutical Group Co.,≠γ® Ltd., Hanso Pharmaceutical)®£↔∞ and AI ) Atomwise, Inc., a leader in the βε£field, announced the collabor∑&♥ation. The purpose of the collab≠♠¥σoration is to design☆÷₹♥ and discover potentδ™±≈ial drug candidates for a total of 11β₹ private target protei ™♥ns in multiple therapeutic areas.A"<✘←tomwise and Hansoh Pharma scientific teams &λεwork closely together in each pro× ¶gram. The combination of complementary expe♣&rtise and technology has th♠♥♥ e potential to drama≈β§↕tically increase succ ₽£ess rates and shorten ♦ ™schedules in drug discovery and clinica™×♠l development.Dr. Aifeng Lyu, President of Jia×Ω•♥ngsu Hansoh Pharmaceutical™"☆£ Group Co., Ltd., a subsidiary of Hansoh P≤"→εharma, said: “Atomwise is the best partner λπ↕ for Hansoh Pharma to use AI technology to innoε™ vate and create diverse small molecule pipeliλ'Ω↔nes in oncology and other th≤'erapeutic areas. I am ve¶ry impressed with the≠→ team and I believe that working toge£≤ther will provide a special opportun©<ε♣ity to develop first-in-cl®∞ass and best-in-class therapeutics. "Dr. Abrah ∑am Heifets, CEO of Atomwise, said: “It iφλ€s a great pleasure for us to partner wiλ≈≈≤th Chinese biopharmaceutical giant Hansoh Pha≤↓™rma. Hansoh Pharma shares our stro £ng commitment to innovation and our missio≤¥n to influence patient health globally.”Atomwi✘₩se's world-class AI pl≠∞∏εatform for structure-based drug design lead©Ωπ☆s the way in finding hit compounds, se ©≈lecting lead compounds from hit compounds, and ★εγoptimizing lead comp$§ounds. Hansoh Pharma will♦♥ contribute in its capacity in biological a★®±∑ssays and medicinal chemistry,αγ and will lead the subsequent preclinical and₹¥× clinical development.Subject to §the terms of the collaborat♣±♥→ion, Atomwise will receive rev¶ ×←enue based on private technology fe™"'<es, option exercise fees, royaltie↔γs, and sublicenses and sales o✔>f assets created under the colla↔✘✔boration. Based on historical average sales of sm&γall molecule drugs, the o☆≠'verall potential value of this transact★ ion for Atomwise may ex∑ceed the potential value of a ↔"←hit drug if all projects succeed. Hγ∑♠ansoh Pharma receives development and commercialization ∑≈>rights in all fields and regions.2019 Asia-pacifλ©ic pharma IP Leader <≥Summit: http://en.zenseegroup.comγα✔'/p/510934/will be held in ×♥Beijing on Novemδ®ber 14-15, and will attract more than 500'£♠ industry experts from domestic and ∞σ≤€foreign pharmaceutica€↓>l companies, biotechnology companies♦δσ , governments, associations, ✘γ☆•law firms, intellectual property agenσ•ts and other companies ®αto attend.Official registration and consultation∏★ channels:Contact：AnnPhon¥δ€♠e: 021-65650305Email：Ma☆Ω rketing@zenseegroup.comhttp://en.zenseegro★δ♥up.com/p/510934/ -
0917
Akari Therapeutics’ Nomacopan Granted ♣γ↕U.S. Orphan Drug Designa≥ ♣©tion for Bullous Pemphigoid
Akari Therapeutics, Plc, a bioph∑↑armaceutical company focused o•∞λσn innovative therapeutics to treat ∏₽εorphan autoimmune and inγπ•flammatory diseases where the c∏ omplement (C5) and/or l←₩₽eukotriene (LTB4) systems are implicated, todaσ♣φ↓y announced that the U.S. Food and Drug Adm₩&inistration (FDA) has granted orphan drug design₽λ'ation for nomacopan for the treatmeβ¶nt of bullous pemphigoid (BP).“ γ>BP, a severe blistering skin condition with ₽ $∑no approved treatments, i♠σφs an exciting therapeutic taδ♦✔♠rget for our lead drug candidate, nomacop ♣≤≈an. It is also a disease of increasing prevalenc∞✔ e due to an aging po≠≥pulation and improving diaΩπΩ gnosis,” said Clive Richardson, Chief Exε>Ωecutive Officer of Akari Th ₹♣erapeutics. “Orphan drug ☆≠÷designation for nomacopan is a maj÷or step forward for the program, pδ↕♠ositioning nomacopan for eligi¥$"♠bility for an additional seven years of marketi<δng exclusivity in BP ≠☆↓if nomacopan is approved by₹•☆ the FDA. This news i'♦'s in addition to the recent orphan drug d∑€₹∏esignation received for our HSCT-TMA program.”Thσ↕☆★e Company plans to rele×"ase new safety and efficacy data from an ongoing •×<Phase II trial with ↑ nomacopan in patients with BP at an oral presenta∏εtion by Dr. Christian Sadik at the 28th Europeφ¥ €an Academy of Dermatology φ↓•and Venereology (EADV) ↓ β¥Congress on October 10, 2019. γΩIn August, the Company★∞ announced new data d∞☆®₹emonstrating the synergistic b♠♣Ωenefits of nomacopan’s✘Ω dual C5 and LTB4 inhibitory activity in φ&pemphigoid disease, generated £♠by Dr. Christian Sadik’s group at University of↑>Ω★ Lubeck, Germany, and published in the Augus☆λ →t 2019 edition of JCI Insight [link].Orpγπhan drug designation by the FDA is granted↕₹↑λ to promote the development of dru≤§gs that target conditions affecting 200,000 or ★ fewer U.S. patients annually and that are ←& expected to provide significant therapeuti≠<c advantage over existin¶εg treatments. Orphan designation qualifi≥es Akari for various benefits, i ∏≈ncluding seven years of market exclusivi®¶ty following marketing approval, tax credε✘←its on U.S. clinical±' trials, eligibility for orphan ≈≠drug grants, and a waiver of certain admini€÷&strative fees.2019 Asia-pacific pharma IP L♥φeader Summit:http://en.zenseegroupβ↑.com/p/510934/will be held in Beijγ™ing on November 14-15,§ and will attract more than 500 i ndustry experts from domestic and foreign pharma✘★'ceutical companies, biotechnology companiγ§es, governments, associati©£→₹ons, law firms, intellectual property agents and♦♠ other companies to atten&↔₹d.Official registration and consultation chann§≤✘els:Contact：AnnPhone: 021-656≥™≈♣50305Email：Marketing@zenseegroup.comh&€≥ttp://en.zenseegroup.com/p/510934/ -
0916
Hansen Pharmaceutical♦δs and Atomwise Launch Strateg×Ω"ic Collaboration on Artificial ≥ Intelligence Drug Discovery in Multiple The Ωrapeutic Areas
China's leading biopharmaceutical σ≈company Hansoh Pharmaceutical Group Company Liπ÷←mited (" Hansen Pharmaceutical ") and d¶γrug discovery artificial intel✔₹ ligence (AI) Atomwise, Inc. (" ≠∑÷Atomwise ") , a leader in the field, announγ"ced a collaborative design and•$ discovery of potential drug candidates×ε₽ for up to 11 unexposed target prot€'♦∑eins in a variety of therapeutic areas. ÷Atomwise and Hansen Pharm♣ε&aceutical's scientific team will &↕¥αwork closely together in these projects. The δ®combination of complem¥±↓entary expertise and technol ₹≈ogy is expected to significantly increase suc×★cess and reduce timelines for drug discovery an≥δd clinical development.Dr. Lσ ₩u Aifeng, President of Jia×'"ngsu Hansoh Pharmaceutical Group Co., Ltd.,®€ said: Hansen Pharmaceutical is committed to u "σsing AI technology to innovate and deve→lop diverse small molecules in the fi§§eld of cancer and other therapeutλics. Atomwise is the righ♣✘t partner for Hansen Pharmace<> &uticals. We are very impressed with Atomwise' ∏×s AI platform, capabilities and team. We b∑×↔&elieve that the two companies will have a© n excellent opportunity to develop s™§>imilar and best-in-class ε→therapeutic drugs. ."Dr. Abraham Heifets, CEO of×∑ Atomwise, said: "We are very excited<← to work with Hansen Pharmaceutical, C§©♦hina's leading biopharmaceutical company. Ha¶✔↓nsen Pharmaceuticals an÷♥d we all have strong commitment to innovationε ★ and a common mission to influence the health σ÷of patients worldwide. ."♥≈→The world-class AI platform for Atomφ÷wise structured drug design will guide efforts in≠δ hit discovery, accide↓εntal discovery to hit-to-lead selection, and oβ ptimization of lead compounds. Han♦sen Pharmaceuticals is committed to biologi£™₽cal testing and pharmaceutical chemistry, as♣↔<€ well as leading subsequent preclinical an✔π↑d clinical development activ≠®∑ities.Under the terms of the →™partnership, Atomwise will receive♦♠σ≈ undisclosed technology royalt ÷•Ωies, optional royalties, royalties, and ✔§ε→subcontracting authorizations or revenue generate ÷d from the sale of the derivative assets. Based π≈ on the historical avera≠πge turnover of small molecule drugs, the™$®♣ potential total value of all successful pσ₽rojects with Atomwise's transaction may exceed€×± potential selling drugs. Hanson Pharma ₽∞♠ceuticals will receive development and ><commercialization rights in all fields and geδ<&ographies.2019 Asia-pacifβ↔≠ic pharma IP Leader Summit: http://en.zenseeg£ε roup.com/p/510934/wil§∏£l be held in Beijing on&nbs©δ§p;November 14-15, and will attract more π☆Ω>than 500 industry experts from domestic and foreign pharmaceutical companies, bio•σ ¥technology companies, governments, associations,♣∑' law firms, intellectual property ≈≤ agents and other companies to att↔ end.Official registration and ✔$consultation channels:Contaλσ×♦ct：AnnPhone: 021-65650305Email：Mark≈↔eting@zenseegroup.com$£http://en.zenseegrou☆§•'p.com/p/510934/ -
0912
I-Mab Biopharma and Junshi Biosc∞¥iences Announce Collaboration to&• Evaluate TJD5 in Combination with Toripalimab
WEDNESDAY, SEPTEMBER 11, 201♥↓¶9I-Mab Biopharma (I-Mab), a China and U.S.-b∏∑₹ased clinical stage biopharmaceutical company excוlusively focused on the d₹¥ iscovery and development of potential first-©π™£in-class and best-in-class biologi↑©<≠cs in immuno-oncology and autoimmun♣σe diseases announces the signin↕©→g of a collaboration agreement with Sφ≠>hanghai Junshi Biosciences Co., Ltd (Junshi Biosc£•iences), an innovation-driven biopharmaceu↓♥¶≈tical company to evaluate the co≤λmbination therapy of I-Mab's ♣÷£TJD5, a proprietary innovative CD7₹$3 antibody with Junshi Bioscie↕∏nces' Toripalimab (Trade na€me: Tuoyi), a recombin×≥×ant humanized anti-PD-1 monoclφ≥★onal antibody in patients with ca Ω★ncers in China.Dr. Jingwu Zang, Founder an↑>÷♦d Chairman of I-Mab, commented, "TJD5 is an innovγ&₩ative CD73 antibody with best-in-₩₹☆ class potential that has±₩✘© entered into Phase I trial in the&↓ US. We are very pleased to collaboΩ♣∑rate with Junshi to explore the ≈∏→clinical synergies with Toripalimab which i©παs an innovative drug with distincti✘₹ve treatment advantages. We are l♦ ooking forward to bringing ₽≈✔more clinical benefits to patients across vario☆÷us cancer types."Dr. Ning Li,™✔> CEO of Junshi Biosciences, commented, "As a•✘n anti multi-tumor drug, toripalimab has sh♠£own good safety and efficacy in cli←•∞nical trials with mono and combin↑ ation therapy. We believe, thr←α ough the cooperation↑↕ with I-Mab, we could continue to €&→explore the combination potential of tor≠ Ω ipalimab and innovative drugs to impα$✘rove the outcomes of immune-oncology therapy, ★↕lightening hope for more patie↕σ®®nts.2019 Asia-pacific pharma IP Leader ¥↑Summit: http://en.ze®σ←nseegroup.com/p/51093γ☆¥4/ will be held i₹×n Beijing on Novembεer 14-15, and will attract more than 500 ind♠₩ustry experts from domestic and foreign pharmaceλ↔utical companies, biotechnology com≈<∞™panies, governments, associations, law ✔ firms, intellectual property agents and₹¥♥¥ other companies to attend.O₹±fficial registration a♥∞$'nd consultation channels:Contact：Anλ<nPhone: 021-65650305Email：Marketing@zenseegroup.← ★comhttp://en.zenseegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016